You are here

Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Novartis cites strong sales growth for $15B Sandoz spin-off as board vote unanimously for separation

Biopharma Reporter

Mon, 08/21/23 - 06:50 pm

Tags:

Novartis, Sandoz, spinoff, biosimilars, generics

Novartis floats share distribution scheme as it plots Sandoz spinoff for Oct. 4

Fierce Pharma

Fri, 08/18/23 - 11:29 am

Tags:

Novartis, Sandoz, spinoffs, generics, biosimilars

Sandoz plans to enter the Eylea biosimilar race

Clinical Trials Arena

Tue, 08/15/23 - 10:03 am

Tags:

Sandoz, generics, biosimilars, Eylea, Novartis, wet age-related macular degeneration

Spinal Muscular Atrophy: Four trials to watch over the next 12 months

Clinical Trials Arena

Fri, 08/11/23 - 11:39 am

Tags:

clinical trials, spinal muscular atrophy, Scholar Rock, apitegromab, Novartis, Zolgensma, Spinraza, clenbuterol

Novartis prepares for FDA submission for its chronic hives treatment

Clinical Trials Arena

Wed, 08/9/23 - 10:15 am

Tags:

Novartis, remibrutinib, chronic hives, FDA

Novartis sickle cell drug’s approval formally revoked by EU regulators

BioPharma Dive

Sun, 08/6/23 - 09:27 pm

Tags:

Novartis, Adakveo, sickle cell disease, Europe, EMA

Biosimilar makers split strategies in bid to take on top-selling Humira

BioPharma Dive

Thu, 07/27/23 - 10:25 am

Tags:

biosimilars, Humira, AbbVie, rebates, drug pricing, Amgen, Celltrion, Novartis, Boehringer Ingelheim, Biocon, Fresenius, Sandoz, Organon, Coherus

Scratching the surface of the urticaria pipeline

EP Vantage

Thu, 07/20/23 - 10:00 am

Tags:

chronic urticaria, Sanofi, Dupixent, Regeneron, Novartis, Roche, Xolair, Allakos, AstraZeneca, Celldex Therapeutics

Novartis raises drug sales forecast, plans new stock buybacks

BioPharma Dive

Tue, 07/18/23 - 10:23 pm

Tags:

Novartis axes secretive obesity program after high-risk, high-reward bet fails

Fierce Biotech

Tue, 07/18/23 - 11:41 am

Tags:

Novartis, obesity, pancreatic cancer

Novartis buys a preclinical biotech and its RNA drug technology

BioPharma Dive

Mon, 07/17/23 - 07:07 pm

Tags:

Novartis, DTxPharma, siRNA, M&A

Novartis retreats from TIGIT, handing $300M candidate back to BeiGene

Fierce Biotech

Tue, 07/11/23 - 10:22 am

Tags:

Novartis, anti-TIGIT, BeiGene

FDA approves label update of Novartis’ Leqvio to treat high LDL-C

Pharmaceutical Business Review

Tue, 07/11/23 - 10:20 am

Tags:

Novartis, Leqvio, inclisiran, LDL-C

Novartis to appeal district court ruling on heart drug patent

BioPharma Dive

Mon, 07/10/23 - 09:28 pm

Tags:

Novartis, Entresto, patents, legal

Biopharma buyouts bounce back

EP Vantage

Wed, 07/5/23 - 10:17 am

Tags:

M&A, Amgen, Astellas, Eli Lilly, GSK, Horizon Therapeutics, Merck, Novartis, Pfizer, Seagen

Bausch + Lomb to acquire Xiidra, ‘front of eye’ assets from Novartis

Healio

Fri, 06/30/23 - 10:10 am

Tags:

Bausch + Lomb, M&A, Novartis, Xiidra, dry eye disease

Ex-Novartis NASH drug clears clinical test, fueling Boston's pursuit of Akero, 89bio

Fierce Biotech

Wed, 06/21/23 - 10:51 am

Tags:

Boston Pharmaceuticals, NASH, Novartis, Akero Therapeutics, 89Bio, BOS-580

CAR-T beyond cancer? Novartis and others say yes

EP Vantage

Mon, 06/19/23 - 10:19 am

Tags:

CAR-T, Novartis, Cabaletta Bio, Cartesian Therapeutics, Bristol Myers Squibb, Gracell, Yake Biotechnology

Sandoz targets barriers to biosimilar accessibility with latest initiative

Pharmaceutical Technology

Thu, 06/15/23 - 07:00 pm

Tags:

Sandoz, Novartis, patient access, biosimilars

Biopharma Confronts a Rising Tide of Ransomware Attacks

BioSpace

Wed, 06/14/23 - 10:11 am

Tags:

cyberattacks, cybersecurity, ransomware, Eisai, Sun Pharma, Novartis, AstraZeneca, Merck

Pages

last 30 twitter posts